19.07.05 New test in lab Flashcards

1
Q

What is verification

A

Confirmation, through the provision of objective evidence, that specified requirements have been fulfilled (doing test correctly). Comparison with existing performance specification.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is validation

A

Confirmation, through the provision of objective evidence, that the requirements for a specific intended use or application have been fulfilled (doing the correct test). Define performance specification (accuracy, limitations, controls).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What framework is used in the process of implementing a test

A

ACCE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does ACCE stand for

A

Analytical validation, clinical validation, clinical utility and consideration of ethical, legal and social implications of the test.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Factors considered when implementing new tests

A
  • Is there a clinical need
  • is there a clinical demand for new service
  • New service have clinical utility
  • Is the test legal/ethical
  • testing strategy
  • How would the new service impact current working practice
  • budget considerations
  • staff skills, education and training
  • Equipment and lab considerations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Is there a clinical need for the service? Things to look for

A
  • Incidence and prevalence of a condition
  • Nature of disease, severe enough to require genetic diagnosis
  • Predisposition to a disease (carrier risk, reproductive counselling)
  • Expected workload
  • Is the service already provided by an alternative accredited lab with sufficient capacity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Factors in deciding if there’s a clinical demand for the new service?

A
  • Who is requesting service. —-Physicians, counsellors, geneticists, patient lead groups
  • Where would referrals come from
  • Is a new service necessary if another lab offers
  • Would it be a definitive diagnostic test or a screening test to rule out a condition (e.g. Fragile X and dev delay.)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Factors in deciding if the service have clinical utility

A
  • Would testing affect treatment or identify an effective drug regimen.
  • Would it provide a diagnosis for a currently unidentified genetic disease, where no test is currently available
  • Identifies low penetrance alleles (HD)
  • Do environmental factors have a contribution to phenotype.
  • Used for other family members (predictive, prenatal testing)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Factors to decide if the test is legal/ethical

A

-Particularly with regard to prenatal/predictive testing
-Reporting incidental findings, data sharing and storage
-Sexing for family balancing
Paternity testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Factors to determine technical testing strategy

A
  • Biochemical, cytogenetic, molecular.
  • Single gene or multigenic
  • hotspots, common path vars
  • Alternative tests: biochemical, histological, clinical. Will other tests be required (methylation)
  • Analytical validity (reliable, reproducible, effective, specific, sensitive)
  • Use of controls
  • Uncertainty of measurement
  • Would it detect intermediate outcomes (mosaics, premutations)or incidental findings.
  • What would be tested- DNA, RNA, chromosomes. Is the material easy to obtain.
  • test samples- easy to obtain, extract. Appropriate for test. e.g. Pallister-killian not seen in blood.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Impact on current working practices

A
  • Increased workload
  • Would staff need training
  • Time required to set up service (validation, purchasing new equipment, training etc)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Considerations if a test is to replace a current one

A
  • Does it improve TAT, is it more sensitive/specific
  • Does TAT fit with clinical need (short enough to act clinically)
  • How much DNA required- less than previous test
  • Are there national guidelines, EQA schemes
  • Has the test been externally validated. How to internally validate/verify
  • What controls are required
  • Will it impact another service, i.e. does it need to be confirmed by another test.. e.g. array CGH reducing karyotyping. MLPA to validation del/dups found by NGS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What budget considerations are there

A
  • Feasible service cost, could it be offered at a competitive price/TAT and cover costs.
  • Is funding available to accommodate introduction of new test
  • Start up cost
  • Recurring costs of on-going testing, maintenance of equipment
  • Is a business case needed
  • Is pharmaceutical company funding available, if result indicates treatment of a drug
  • billing procedure for service users
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Implications on staff skills, education and training

A
  • Determine workload and staffing requirements. i.e. expected number of samples, amount of work per sample.
  • Do staff already have adequate training. Is internal/external training required. Internal/external support for troubleshooting and clinical advice. Enough competent staff to run service (staffing structure). Can you recruit new scientists with appropriate exp and skills.
  • IT bioinformatic support, data storage requirements. LIMS functionality.
  • Health and safety aspects. Implementing SOPs, internal QC, risk assessments, COSHH.
  • Test development in house or require expensive kits/ equipment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Equipment and laboratory considerations

A
  • determine the best tests for service, including hands on time, throughput, sensitivity and cost.
  • Requirements for new equipment. Leased/ bought outright. Will capital funding be required from trust.
  • Start up and maintenance/running costs of equipment.
  • If new equipment required can it be used for other services (current and in future).
  • Can current equipment be used for service. Will equipment cover demand
  • Does a cheaper test exist. Can testing be automated.
  • Suitable space in current premises to carry out new test. New space required or current space re-arranged.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Population factors

A
  • incidence of disease in total population.
  • Does incidence warrant new service (e.g. if very rare)
  • Will service be national or regional. If national can sample arrive quickly enough.
  • Other considerations: reduced penetrance, variable expressivity, pre-mutation, recessive carrier.
  • Ethnicity of the population. Do certain populations have higher prevalence (e.g. Ashkenazi Jews- Tays Sachs 1/27 carriers)
  • Are certain variants seen in all population types or in certain ethnic populations.
  • Broad population spectrum testing/ validation, that takes into account ethnicity.
  • Other factors like socioeconomic, environmental, co-morbidities, age, gender that may affect accuracy of testing.
17
Q

Background work

A
  • Disease: clinical aspects (acceptance criteria agreed with clinicians), inheritance pattern, genetic causes.
  • Technical: equipment/reagents required, controls, design assay.
18
Q

Validation work

A
  • Adjust protocols if required.
  • Write SOPs
  • Screen anonymised samples (positive)
  • test control samples in parallel (old vs new). Demonstrate accuracy, repeatability, reproducibility, robustness.
  • Audits to assess new test (examination, vertical and horizontal). Look for quality improvements, non-compliances.
  • Review figures. Expected vs observed numbers of referrals. Pick up rate as expected.
  • Relevant EQA schemes available? If not can you cross-lab test
  • Meet ISO requirements?
19
Q

Implement service

A
  • Staff are appropriately trained
  • SOPs authorised
  • Managing workloads- batching samples for testing
  • Design worksheets, sample database
  • Design report templates. Riders, cut-off values etc.
  • Advertise service: lab website, UKGTN, ACGS, BSMG, conferences.
  • Audit of requests, results.
  • Submit variants onto public databases
  • Write gene dossier or BP guidelines.
20
Q

Feedback from users

A
  • Surveys, user group meeting

- Act on feedback to optimise service

21
Q

On going verification

A
  • Periodic review of trends when in routine use.

- Recording process variations (errors/incidents).